How Does Celcuity’s (CELC) Russell Index Exit Reframe Its Gedatolisib-Centered Investment Story?

• On 27 June 2026, Celcuity Inc. was removed from several Russell indexes, including the Russell 3000E, Russell Microcap, and multiple related growth and value benchmarks.
• This broad index removal matters because it can prompt index-tracking funds to adjust their holdings, potentially altering Celcuity’s shareholder base and trading patterns.
• With Celcuity’s removal from multiple Russell benchmarks now in the past, we’ll explore how this index exit interacts with its gedatolisib-driven investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Celcuity Investment Narrative Recap

To own Celcuity, you need to believe gedatolisib can become a meaningful treatment option in HR positive, HER2 negative breast cancer and eventually other tumors, despite today’s zero revenue and heavy losses. The key near term catalyst is the upcoming FDA decision on gedatolisib, alongside ongoing VIKTORIA 2 progress. Celcuity’s broad removal from Russell indexes primarily affects trading and index ownership, not these clinical and regulatory milestones, so I do not see it as a material change to that core story.

In my view, the most relevant recent announcement is the June 2 update that detailed VIKTORIA 1 PIK3CA mutant efficacy and safety data and confirmed FDA Priority Review for gedatolisib, with a July 17, 2026 PDUFA goal date. This concentrates attention on a single, time bound regulatory decision as the main catalyst, while the index removal highlights how quickly sentiment and liquidity can shift around a pre revenue biotech in the weeks leading up to such an event.

Yet beneath the excitement about a potential approval, the combination of rising operating losses and significant debt, including the US$500,000,000 term loan facility, is something investors should be aware of...

Read the full narrative on Celcuity (it's free!)

Celcuity's narrative projects $817.9 million in revenue and $267.5 million in earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value, a 61% upside to its current price.

Exploring Other Perspectives

While consensus leans on approval and broad uptake, the most pessimistic analysts were only assuming about US$414,400,000 of revenue and US$129,700,000 of earnings by 2029, so this index exit could easily reshape how you weigh those risks and it is worth considering how your own expectations compare.

Explore 4 other fair value estimates on Celcuity - why the stock might be worth over 8x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com